The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Early Diagnosis of Pancreatic Cancer: Challenges and New Developments
Open accessAbstract
Pancreatic cancer is a lethal malignancy with its incidence almost equivalent to mortality. The complex pathophysiology, absence of early diagnostic and prognostic markers and unresponsiveness to radiation and chemotherapies are major barriers against successful therapy. Poor performance of therapeutic agents, even in the initial stage of invasive cases, emphasizes the importance of early detection for improved survival. The present review discusses the challenges and advances in biomarkers including serological signatures, circulating tumor cells, autoantibodies, epigenetic markers and miRNAs that are being explored to detect this cancer at early stages. Considering the long time gap between the development of malignant lesions and full-blown primary and metastatic pancreatic cancer, unique opportunities are being contemplated for the development of potential diagnostic and prognostic markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317
Hereditary Pancreatitis and the Risk of Pancreatic Cancer
Lowenfels, A. B., Maisonneuve, P., DiMagno, E. P., Elitsur, Y., Gates, L. K., Perrault, J., Whitcomb, D. C., & International Hereditary Pancreatitis Study Group (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.6.442 · Cited by 988
Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies
Ben, Q., Xu, M., Ning, X., Liu, J., Hong, S., Huang, W., Zhang, H., & Li, Z. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.003 · Cited by 685
Prevalence and Clinical Profile of Pancreatic Cancer–Associated Diabetes Mellitus
Pannala, R., Leirness, J. B., Bamlet, W. R., Basu, A., Petersen, G. M., & Chari, S. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.039 · Cited by 621
Brentnall, T. A., Bronner, M. P., Byrd, D. R., Haggitt, R. C., & Kimmey, M. B. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00003 · Cited by 391
Gangi, S., Fletcher, J. G., Nathan, M. A., Christensen, J. A., Harmsen, W. S., Crownhart, B. S., & Chari, S. T. (2004) · American Journal of Roentgenology · doi:10.2214/ajr.182.4.1820897 · Cited by 249
Molecular markers of early pancreatic cancer
Goggins, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.19.711 · Cited by 214
Cited by
Chemoresistance in Pancreatic Cancer
Zeng, S., Pöttler, M., Lan, B., Grützmann, R., Pilarsky, C., & Yang, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184504 · Cited by 611
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes
Hidalgo, M., Cascinu, S., Kleeff, J., Labianca, R., Löhr, J.-M., Neoptolemos, J., Real, F. X., Van Laethem, J.-L., & Heinemann, V. (2015) · Pancreatology · doi:10.1016/j.pan.2014.10.001 · Cited by 509
Mucins in pancreatic cancer and its microenvironment
Kaur, S., Kumar, S., Momi, N., Sasson, A. R., & Batra, S. K. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.120 · Cited by 301
Self-citationMulticenter study of early pancreatic cancer in Japan
Kanno, A., Masamune, A., Hanada, K., Maguchi, H., Shimizu, Y., Ueki, T., Hasebe, O., Ohtsuka, T., Nakamura, M., Takenaka, M., et al. (2018) · Pancreatology · doi:10.1016/j.pan.2017.11.007 · Cited by 291
“There are several reasons for the difficulties in the early diagnosis of pancreatic cancer including the absence of early-stage biomarkers, anatomical location in the retroperitoneum allowing invasion to the surrounding organs and blood vessels, and non-specific symptoms [6, 7].”
BackgroundCurrent status and progress of pancreatic cancer in China
Lin, Q.-J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i26.7988 · Cited by 285
Pancreatic Cancer: Pathogenesis and Diagnosis
Goral, V. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.14.5619 · Cited by 259
Nagata, N., Nishijima, S., Kojima, Y., Hisada, Y., Imbe, K., Miyoshi-Akiyama, T., Suda, W., Kimura, M., Aoki, R., Sekine, K., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.03.054 · Cited by 209
Identification of a three-biomarker panel in urine for early detection of pancreatic adenocarcinoma
Radon, T. P., Massat, N. J., Jones, R., Alrawashdeh, W., Dumartin, L., Ennis, D., Duffy, S. W., Kocher, H. M., Pereira, S. P., Guarner (posthumous), L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2467 · Cited by 203
Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis
Nie, S., Lo, A., Wu, J., Zhu, J., Tan, Z., Simeone, D. M., Anderson, M. A., Shedden, K. A., Ruffin, M. T., & Lubman, D. M. (2014) · Journal of Proteome Research · doi:10.1021/pr400967x · Cited by 128
Early Diagnosis of Pancreatic Cancer: The Key for Survival
Gheorghe, G., Bungau, S., Ilie, M., Behl, T., Vesa, C. M., Brisc, C., Bacalbasa, N., Turi, V., Costache, R. S., & Diaconu, C. C. (2020) · Diagnostics · doi:10.3390/diagnostics10110869 · Cited by 100
“Unlike EUS, these techniques have a number of disadvantages like low sensibility in the detection of adenopathies less than 1 cm in size, risk of developing complications like iatrogenic acute pancreatitis (post ERCP), or high cost [73].”
BackgroundToshima, F., Watanabe, R., Inoue, D., Yoneda, N., Yamamoto, T., Sasahira, N., Sasaki, T., Matsuyama, M., Minehiro, K., Tateishi, U., et al. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.26014 · Cited by 81
Qureshi, T. A., Gaddam, S., Wachsman, A. M., Wang, L., Azab, L., Asadpour, V., Chen, W., Xie, Y., Wu, B., Pandol, S. J., et al. (2022) · Cancer Biomarkers · doi:10.3233/cbm-210273 · Cited by 79
Noninvasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in Urine
Arasaradnam, R. P., Wicaksono, A., O’Brien, H., Kocher, H. M., Covington, J. A., & Crnogorac-Jurcevic, T. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.09.054 · Cited by 73
Kang, M., Qin, W., Buya, M., Dong, X., Zheng, W., Lu, W., Chen, J., Guo, Q., & Wu, Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.031 · Cited by 63
Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
Lei, F., Xi, X., Batra, S. K., & Bronich, T. K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255786 · Cited by 51
Self-citationBiomarkers for early diagnosis of pancreatic cancer
Jenkinson, C., Earl, J., Ghaneh, P., Halloran, C., Carrato, A., Greenhalf, W., Neoptolemos, J., & Costello, E. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.965145 · Cited by 42
Metadata
- Authors
- Kaur, S., Baine, M. J., Jain, M., Sasson, A. R., & Batra, S. K.
- Venue
- Biomarkers in Medicine
- Publisher
- Informa UK Limited
- Published
- 2012-10
- Volume
- 6
- Issue
- 5
- Pages
- 597-612
- ISSN
- 1752-0363 (ISSN-L)
- 1752-0371
- OpenAlex
- W2073816554
- Cited by
- 220
- References
- 13
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.